rs121918393 — APOE Christchurch (R136S)

Ultra-rare APOE3 missense variant that dramatically reduces HSPG binding and tau propagation, conferring near-complete resistance to Alzheimer's disease in the homozygous state and a modest protective delay in heterozygotes

See your personal result for APOE

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Christchurch Mutation — Nature's Blueprint for Alzheimer's Resistance

Apolipoprotein E (ApoE) is the most powerful common genetic determinant of Alzheimer's disease risk in the human genome. The APOE4 allele increases lifetime risk 3–4 fold in heterozygotes and 8–12 fold in homozygotes; APOE2 is modestly protective. But in 2019, a third piece of the puzzle emerged: an ultra-rare variant called APOE3 Christchurch (R136S), carried in homozygous form by a single Colombian woman, appeared to nearly abolish Alzheimer's disease pathology despite her carrying the most penetrant familial AD mutation known — PSEN1 E280A, which causes dementia in virtually all carriers by their late 40s.

Arboleda-Velasquez et al. 201911 Arboleda-Velasquez et al. 2019
Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine reported that this woman did not develop mild cognitive impairment until her 70s — nearly 30 years after the expected onset of ~44 years in her 1,200-member kindred. Brain imaging revealed unusually high amyloid burden but remarkably limited tau pathology and preserved metabolism in AD-vulnerable regions. The implication: the Christchurch mutation somehow broke the link between amyloid accumulation and downstream tau-driven neurodegeneration.

The Mechanism

The R136S substitution — arginine to serine at position 136 of the mature protein (154 in the pre-protein, hence the dual nomenclature R136S / p.Arg154Ser) — falls squarely within the heparan sulfate proteoglycan (HSPG) binding domain22 heparan sulfate proteoglycan (HSPG) binding domain
HSPGs are abundant cell-surface and extracellular matrix proteins that act as co-receptors for ApoE. The Christchurch substitution dramatically weakens HSPG affinity.

This matters because HSPG binding drives several of ApoE's most damaging effects in the AD brain. Wang et al. 2023 (Nature Neuroscience)33 Wang et al. 2023 (Nature Neuroscience) showed that the homozygous R136S mutation rescued APOE4-driven phosphorylated tau accumulation, neuroinflammation, and neurodegeneration in both mouse tauopathy models and human iPSC-derived neurons. Single-nucleus RNA sequencing demonstrated that R136S increased disease-protective and reduced disease-associated cell populations in a gene-dose-dependent manner — homozygotes showed full rescue, heterozygotes partial.

Two additional mechanisms have since been characterized. Zhang et al. 2024 (Neuron)44 Zhang et al. 2024 (Neuron) found that the R136S mutant protein directly binds tau with higher affinity than wild-type ApoE3, blocking tau uptake into neurons and microglia and reducing tau fragmentation by the asparagine endopeptidase AEP — a key step in tau propagation. Separately, Wang et al. 2024 (Immunity)55 Wang et al. 2024 (Immunity) demonstrated that R136S inhibits the cGAS-STING interferon pathway, suppressing the chronic neuroinflammatory signaling that amplifies tau pathology.

On the lipid side, the same HSPG/LDL-receptor-related protein binding domain affected by R136S is required for efficient clearance of triglyceride-rich remnant lipoproteins. This means heterozygotes and homozygotes for the Christchurch allele can develop type III hyperlipoproteinemia66 type III hyperlipoproteinemia
a.k.a. dysbetalipoproteinemia; impaired clearance of IDL and VLDL remnants causing elevated total cholesterol and triglycerides, particularly when combined with other dyslipidemia-predisposing factors.

The Evidence

The founding 2019 case report was remarkable but N=1. Subsequent research has substantially broadened the evidence base.

Saez-Calveras et al. 2023 (Mol Neurodegeneration)77 Saez-Calveras et al. 2023 (Mol Neurodegeneration) analyzed 455,306 UK Biobank participants and identified 37 heterozygous APOEch carriers (36 European, 1 admixed American; median age 68.6 years). None had developed AD or MCI by the data freeze. Carriers showed lower apolipoprotein B levels and a significantly reduced polygenic risk score for AD (p=0.02). The allele frequency in UK Biobank was approximately 0.004%.

Lopera et al. 2024 (NEJM)88 Lopera et al. 2024 (NEJM) quantified the heterozygous effect in the Colombian PSEN1 E280A kindred: among 27 heterozygous APOEch carriers, median MCI onset was 52 years versus 47 years in matched non-carriers — a 5-year delay, statistically significant (p<0.001). Two heterozygous carriers who underwent brain imaging showed relatively preserved FDG-PET metabolic activity in AD-vulnerable regions. Four autopsy specimens from APOEch carriers showed fewer vascular amyloid deposits. The protective effect is real in heterozygotes, but substantially more modest than in the original homozygous case.

The overall allele frequency is approximately 1–4 per 100,000 in European populations and even rarer in other ancestries. The probability of inheriting two copies (homozygous, as in the Colombian case) is therefore roughly 1 in 600 million to 1 in 6 billion — making the original case effectively unique in human clinical history.

Practical Actions

For the overwhelming majority of people tested, this SNP will return the wild-type CC genotype — the Christchurch allele is too rare to appear in most population samples. The primary clinical relevance is for individuals who carry the AC genotype (heterozygous):

The 5-year delay in PSEN1 E280A carriers is meaningful and suggests that even a single copy of the Christchurch allele provides real neurological protection, likely through partial reduction in HSPG binding and partial tau propagation block. Heterozygous carriers should monitor lipid panels carefully, as the same HSPG/LDL-receptor binding impairment that protects the brain can impair remnant lipoprotein clearance. This is not a reason to treat aggressively, but it is a reason to track.

The Christchurch mutation is now the leading molecular template for next-generation Alzheimer's drug development. Mimetic antibodies that block the HSPG-binding domain of wild-type ApoE are in preclinical development, and the variant itself is being explored for AAV gene delivery as a therapeutic.

Interactions

The Christchurch mutation's protection is most dramatic on an APOE3 backbone (the original Colombian case was APOE3/APOE3-ch). Subsequent work has shown R136S is also protective on an APOE4 background — Wang et al. 202399 Wang et al. 2023 demonstrated R136S on APOE4 rescued most tau and neuroinflammation endpoints in model systems, though with somewhat attenuated effect compared to APOE3 background.

The two canonical APOE isoform SNPs — rs4293581010 rs429358 (the ε4-defining Cys112Arg) and rs74121111 rs7412 (the ε2-defining Arg158Cys) — both fall in the LDL receptor binding region of ApoE and influence AD risk through overlapping but distinct mechanisms. The Christchurch mutation falls in the HSPG-binding subdomain adjacent to the LDL receptor binding site, and its protection is at least partially independent of APOE isoform, as shown by the iPSC data generating APOE2ch, APOE3ch, and APOE4ch constructs.

For individuals with a family history of early-onset Alzheimer's disease, both rs759326281212 rs75932628 (TREM2 R47H) and rs38511791313 rs3851179 (PICALM) influence microglial clearance of amyloid and tau — the same downstream pathways Christchurch modulates — and would be relevant to examine in conjunction.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Common APOE3 sequence — no Christchurch protection

The APOE3 Christchurch (R136S) allele is so rare that its absence carries no inferential weight about disease risk. The absence of a lottery ticket does not mean you have lost the lottery — it means you were never entered. Your Alzheimer's risk is shaped by common variants, particularly the APOE ε4 allele (rs429358) which is present in ~25% of Europeans and increases risk 3-12-fold depending on copy number, along with dozens of other variants in immune-response and amyloid-clearance genes. If Alzheimer's disease prevention is a priority, the most impactful genetic context to understand is your APOE ε2/ε3/ε4 isoform type.

AC Christchurch Carrier Beneficial

One copy of the Christchurch mutation — reduced HSPG binding and partial Alzheimer's protection

Heterozygous carriers show intermediate HSPG binding affinity — one allele produces wild-type ApoE, the other produces Christchurch-mutant ApoE with reduced HSPG affinity. The resulting mix partially attenuates the HSPG-dependent mechanisms through which ApoE promotes tau propagation and neuroinflammation.

The UK Biobank study (N=455,306) found that among 37 identified heterozygous carriers, none had developed AD or MCI by the data freeze (median age 68.6, maximum 82 years), though the sample size and age distribution preclude strong conclusions. Carriers showed statistically significant reductions in AD polygenic risk score (p=0.02) and in apolipoprotein B levels, the latter consistent with partial impairment of LDL/remnant lipoprotein clearance through HSPG and LDL receptor-related pathways.

An important caveat: a 2020 case report (PMID 33095930) described a heterozygous APOEch carrier without PSEN1 mutations who did develop Alzheimer's disease in her 60s — suggesting that a single copy is not uniformly protective and that APOE isoform background and other genetic modifiers matter substantially.

The same HSPG-binding impairment that reduces tau propagation risk also impairs remnant lipoprotein clearance. Monitor lipid panels, particularly IDL and VLDL fractions, especially if other dyslipidemia risk factors are present.

AA Christchurch Homozygote Beneficial

Two copies of the Christchurch mutation — near-complete abolition of tau pathology and Alzheimer's neurodegeneration

Homozygous Christchurch status produces ApoE that has dramatically reduced affinity for heparan sulfate proteoglycans and LDL receptor-related protein receptors. Multiple independent mechanisms are now characterized: reduced tau propagation (ApoE3 R136S binds tau directly and blocks its uptake into neurons and microglia); suppressed cGAS-STING neuroinflammatory signaling; and reduced APOE4-mediated disease-associated microglial activation. In APOE4 mouse models, the homozygous R136S mutation rescued essentially all tau and neuroinflammation endpoints — effects that were only partial in heterozygotes.

Given that this genotype is almost certainly unique in recorded medical history, the evidence for individual-level outcome prediction is necessarily case-level. The mechanistic data from cell and mouse models provides a plausible explanation for the remarkable case, and the subsequent heterozygote data (5-year protection in 27 PSEN1 carriers) supports a dose-response relationship. But the homozygous state cannot be characterized statistically in a population sense.

One significant liability: the HSPG/LRP binding impairment that underlies the neuroprotection also substantially impairs clearance of triglyceride-rich lipoprotein remnants. The original Christchurch variant was first identified in patients with type III hyperlipoproteinemia. Homozygous carriers need careful lipid management — not because cardiac risk can override the neuroprotection, but because dyslipidemia requires its own active management.

If this result appears in a clinical WGS report, verify it rigorously with orthogonal sequencing before drawing conclusions — homozygous results are susceptible to sample handling and informatic errors, and a false positive in this context would be highly misleading.